MaaT Pharma Targets Late 2027 for First Human Trial of MaaT034, Subject to Funding and Regulatory Approval

Bitget2026/10/19 18:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MaaT Pharma received positive FDA feedback on October 19, 2026, supporting development of MaaT034 for solid tumors.
The FDA indicated no additional nonclinical safety studies were needed, pending final meeting confirmation and review of the full investigational new drug application.
A first-in-human trial could begin in late 2027, subject to regulatory clearance and adequate financing.
With cash runway extending through December 2026, the company is exploring investor funding and strategic partnerships to support clinical development.
Previously presented preclinical results supported MaaT034's potential to enhance antitumor activity alongside immunotherapy; the candidate remains in preclinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MaaT Pharma Targets Late 2027 for First Human Trial of MaaT034, Subject to Funding and Regulatory Approval

You may also like

Crypto prices